President and CEOOfficers of the CorporationBoard of TrusteesLeadership CouncilHistory
Managing DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsInfo for Healthcare ProfessionalsJoslin Clinical Guidelines50-Year Medalist Program
Patient PortalAdult ClinicPediatricsEye CareMake an AppointmentBillingInfo for Healthcare Professionals
Directory of Joslin InvestigatorsDiabetes Research Center Alumni ConnectionVolunteer for Clinical Research Studies
Media RelationsNews ReleasesInside JoslinSocial Media
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternationalCommercialization and VenturesJoslin Institute for Technology Translation (JITT)
Give NowHigh Hopes FundWays to GivePlanned GivingEventsGet InvolvedCorporate & Foundation SupportOur DonorsDevelopment Team

Diabetes Innovation 2012

Day 1: Sunday, September 23 | Day 2: Monday, September 24 | Day 3: Tuesday, September 25

   Day 3: Tuesday, September 25, 2012
6:30 AM Networking Breakfast

7:30 Welcome: Partnership and Collaboration Announcements

Centers for Medicare and Medicaid Innovation (CMMI) Challenge Update: News from the Front

  • Deliver better care at lower costs through continuous process improvement
  • Identify, validate and scale innovative models to provide all beneficiaries with a seamless care experience
  • Ensure patients receive the right care, at the right time, in the right setting—every time
   Moderator: Edward Horton, MD, Joslin Diabetes Center
   Jim Hester, PhD, Centers for Medicare and Medicaid Innovation (CMMI)

8:30 – 12:00 SPOTLIGHT
Clinical Technology Breakthroughs

   Moderator: Sachin H. Jain, MD, MBA, Merck

8:30   The Artificial Pancreas—A Holy Grail for Type 1 Diabetes?
  • Is this the next best thing to a diabetes cure?
  • What are the risks of an artificial pancreas if not properly designed?
   Henry Anhalt, DO, Animas Corporation

9:00 Surgical “Cures” For Diabetes?
  • Duodenal-jejunal bypass for type 2 diabetes sparks a metabolic change, causing blood sugar levels to drop and seeming to cure diabetes
  • What are the clinical and financial implications of this “cure”?
   Philip Schauer, MD, Cleveland Clinic
   David Cummings, MD, University of Washington

9:30 Break

9:45 Stopping Before You Start:
New Technologies for Risk Identification and Screening

  • How recent findings can improve diabetes risk prediction through metabolite levels
  • Identify those at highest risk of developing diabetes with new technologies to start preventive measures early
   Robert E. Gerszten, MD, Massachusetts General Hospital
   David VanAvermaete, VeraLight

10:15 Microchip-Based Implants for Managing Diabetes:
How, Why and What about Safety and Security?

  • Roll out microchip technology, benefits and considerations
  • Evaluate clinician and patient data needs
  • Discuss security challenges and possible approaches
   Robert Farra, MicroCHIPS
   Kevin Fu, PhD, UMASS; University of Michigan

10:45 The Quantified Self on Steroids:
Innovation in Devices, Pumps and Monitors

  • How effective is technology for diabetes management?
  • What is the future of technology in type 1 diabetes?
   Howard Wolpert, MD, Joslin Diabetes Center

11:15   Clinical Applications in Diabetes Population Health:
The Good, the Bad and the Ugly

  • Evaluate the impact of clinical diabetes applications on A1C and LDL testing rates and laboratory values
  • Is participation in diabetes population health programs associated with appropriate clinical control of A1C and LDL values?
  • Do members of all ages benefit from participation in diabetes population health programs?
  • Discuss future applications for diabetes in population health management from a joint venture
   Moderator: Martin J. Abrahamson, MD, FACP, Joslin Diabetes Center
   Terry Golash, MD, Aetna
   James L. Holly, MD, Southeastern Texas Medical Association (SETMA)
   Brandon Savage, MD, Caradigm

12:00 PM Challenge Grant Announcements and Private Funding Opportunities
  • Foster radical rethinking of diabetes control approaches and impact measures given the scale of the epidemic
  • Diabetes Innovation Challenge: Create a contest shaped by “public crowdsourcing” for the best innovations to help people living with diabetes
  • Challenge grants for patient engagement technologies
  • Innovation in philanthropy: Supporting pioneering projects that bring fresh thinking and unconventional approaches to bear on the mostpressing health and health care problems
  • More!
   Wil Yu, US Department of Health and Human Services (HHS)
   Patricia Doykos, Bristol-Myers Squibb Foundation
   Angela Moskow, Sanofi US
   Brian C. Quinn, PhD, Robert Wood Johnson Foundation

1:00   Next Steps, Follow-up Plans and Adjourn

   John L. Brooks III, Joslin Diabetes Center

Page last updated: October 26, 2016